Latest Commercialization News

Strategic Elements Ltd (ASX:SOR) advanced its Energy Ink™ technology and commenced a pilot deployment of its EdgeiQ system at a WA gold mine, while maintaining a solid cash position of A$2.87 million and no debt.

Janus Electric has begun generating export revenue in the US while expanding its electric truck fleet to 28 vehicles and significantly improving its cash position through a $1.4 million R&D tax refund and a $2.75 million finance facility.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Bass Oil’s March quarter saw a 13% production dip due to Cooper Basin rains but secured key gas field acquisitions, a $3.5 million grant, and completed a $3 million capital raise.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.

Axtec Limited has sold its PaySure loan book to Real Flow and secured a minority stake in the fintech, marking a strategic shift towards a platform-focused, AI-driven distribution model.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.

FortifAI’s Nol8 FPGA appliance dramatically reduces AI infrastructure costs by replacing up to 60,000 CPUs, slashing annual operational expenses from millions to tens of thousands of dollars.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Xamble Group stabilised revenue at A$1.64 million in Q1 2026 while narrowing its group EBITDA loss slightly despite ramped-up technology spending. The company completed its acquisition of YouthsToday, tripling its influencer base and locking in three commercial contracts worth A$1.17 million.